- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06666322
Platform Trial For Cryptococcal Meningitis (PLATFORM-CM) (PLATFORM-CM)
Platform Trial For Cryptococcal Meningitis
Cryptococcal meningitis is a fungal infection that causes a severe syndrome of meningitis that is 100% fatal without antifungal therapy. Even with antifungal therapy, mortality rates remain high, especially in low and middle income countries where the ongoing HIV/AIDS pandemic increases the risk of cryptococcosis among persons living with HIV infection. The combination of amphotericin and flucytosine (5-FC) has been the mainstay of therapy for the initial management of cryptococcal meningitis for 4 decades. Indeed, the effective delivery of these first line therapy in Africa can lower mortality to 25%. However, several challenges exist. First, even while 5-FC is included on the WHO list of essential medicines, the availability of 5-FC worldwide is limited. Second, liposomal amphotericin (Ambisome ®) is currently available from a single source supplier, creating risk. Third, current therapies have substantial toxicity. Lastly, with widespread agricultural fungicide use of azoles, the median fluconazole minimum inhibitory concentration (MIC50 ) for Cryptococcus has doubled since 2013. Globally, new or improved antifungals are needed for cryptococcal meningitis, particularly those which have less toxicity, greater efficacy, a prolonged half-life, and minimal drug-drug interactions.
As multiple new antifungal medicines are on the horizon, this platform trial utilizes a master protocol to investigate, multiple antifungal regimens using standardized eligibility criteria, standardized study schedule of events, and standardized contemporary endpoints.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Contact
- Name: David Boulware, MD, MPH
- Phone Number: 612-624-9996
- Email: coat.trial@gmail.com
Study Locations
-
-
-
Kampala, Uganda
- Recruiting
- Infectious Diseases Institute
-
Contact:
- David Meya, PhD
- Email: david.meya@gmail.com
-
Mbarara, Uganda
- Recruiting
- Mbarara University of Science and Technology
-
Contact:
- Conrad Muzoora, MBChB MMed
- Phone Number: 256772547175
- Email: conradmuzoora@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- CSF cryptococcal antigen (CrAg) positive meningitis
- Living with HIV
- Ability and willingness to provide informed consent
- Willing to receive protocol-specified lumbar punctures
- Age >= 18 years
- Female participants of childbearing potential who are participating in sexual activity that could lead to pregnancy must agree to use reliable forms of contraception (duration will be indicated in each Trial Appendix).
Exclusion Criteria:
- Received 3 or more doses of antifungal therapy for meningitis within last 30 days
- Inability to take enteral (oral or nasogastric) medicine
- Cannot or unlikely to attend regular clinic visits
- Receiving chemotherapy or corticosteroids
- Receiving hemodialysis or known liver cirrhosis
- Suspected Paradoxical immune reconstitution inflammatory syndrome (IRIS)
- Pregnancy or breastfeeding
- Previous administration of investigational study drug
- Any condition for which participation would not be in the best interest of the participant or that could limit protocol specified assessments
- Trial Appendix study-drug specific eligibility criteria
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Control group
randomized to standard of care
|
2022 WHO First Line Induction Therapy:
|
|
Experimental: Experimental group 1
randomized to experimental antifungal therapy #1
|
Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51)
|
|
Experimental: Experimental group 2
randomized to experimental antifungal therapy #2
|
SF001 2.0 mg/kg IV administered on day 1, followed by 1.5 mg/kg on day 8 with Fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
|
|
Experimental: Experimental group 3
randomized to experimental antifungal therapy #3
|
SF001 3.0 mg/kg IV administered on day 1, 8, and 15 with fluconazole 1200mg/day and flucytosine 100mg/day in divided doses x 14 days
|
|
Experimental: Experimental group 4
randomized to experimental antifungal therapy #4
|
Oteseconazole, is an azole metalloenzyme inhibitor targeting the fungal sterol, 14α demethylase (CYP51) ● Loading doses of oral Oteseconazole 600 mg twice daily for 12 days, then 600 mg oteseconazole weekly on weeks 3 to 12. ● Liposomal Amphotericin B 10 mg/kg IV once.
● Flucytosine 100mg/kg given for 7 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Rate of cerebrospinal fluid (CSF) Cryptococcus clearance (Early Fungicidal Activity, or EFA)
Time Frame: 2 weeks
|
quantified by the change of log 10 Cryptococcus CFU/mL CSF/day as measured by serial quantitative CSF fungal cultures over ~2 weeks.
|
2 weeks
|
|
All-cause mortality
Time Frame: 2 weeks
|
measured at 2-weeks
|
2 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
18-week survival time
Time Frame: 18 weeks
|
18 weeks
|
|
|
Desirability of Outcome Response (DOOR) as ordinal ranked maximum score tested by Win Ratio.
Time Frame: 18 weeks
|
|
18 weeks
|
|
Survival time through 18 weeks without Cryptococcus culture-positive relapse of meningitis
Time Frame: 18 weeks
|
number of participants
|
18 weeks
|
|
CSF culture sterility (cumulative incidence over 18 weeks)
Time Frame: 18 weeks
|
18 weeks
|
|
|
Use of rescue/additional IV amphotericin beyond scheduled use
Time Frame: 18 weeks
|
18 weeks
|
|
|
Modified Rankin score on functional status at 18 weeks
Time Frame: 18 weeks
|
18 weeks
|
|
|
Incidence of laboratory abnormalities by Grade 1-5
Time Frame: 10 weeks
|
10 weeks
|
|
|
Incidence of serious adverse events
Time Frame: 18 weeks
|
18 weeks
|
|
|
Incidence of study drug discontinuation or interruption >1 day due to toxicity, by adverse event grade.
Time Frame: 10 weeks
|
10 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: David R Boulware, MD, MPH, University of Minnesota
- Principal Investigator: David B Meya, MBChB, MMed, PhD, Uganda
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Blood-Borne Infections
- Neuroinflammatory Diseases
- Urogenital Diseases
- Genital Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Immune System Diseases
- Infections
- RNA Virus Infections
- Virus Diseases
- Communicable Diseases
- Sexually Transmitted Diseases, Viral
- Sexually Transmitted Diseases
- Lentivirus Infections
- Retroviridae Infections
- Immunologic Deficiency Syndromes
- Slow Virus Diseases
- Bacterial Infections and Mycoses
- Central Nervous System Infections
- HIV Infections
- Meningitis, Fungal
- Central Nervous System Fungal Infections
- Mycoses
- Cryptococcosis
- Meningitis
- Acquired Immunodeficiency Syndrome
- Meningitis, Cryptococcal
- Health Services Administration
- Health Care Quality, Access, and Evaluation
- Quality of Health Care
- Quality Indicators, Health Care
- Standard of Care
Other Study ID Numbers
- IDIM-2024-32879
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.